Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer
In a new single-arm study, researchers at The University of Texas MD Anderson Cancer Center reported that radiation therapy as monotherapy is a safe and effective noninvasive treatment for oligometastatic renal cell carcinoma (RCC). The findings were published today in The Lancet Oncology.
Led by Chad Tang, M.D., assistant professor of Radiation Oncology, the MD Anderson RCC Oligometastasis Phase II trial is the first study to...
Anil Sood, M.D., elected to the National Academy of Medicine
Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine, has been elected to the National Academy of Medicine (NAM) for...
ATR inhibitor RP-3500 demonstrates safety and early clinical benefit
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500...
Caroline Chung, M.D., named MD Anderson’s first Chief Data Officer
The University of Texas MD Anderson Cancer Center today named Caroline Chung, M.D., associate professor of Radiation Oncology and Diagnostic Radiology, the new vice president and chief data officer (CDO), effective Oct. 1.
As the institution’s first-ever CDO, Chung will be responsible for shaping MD Anderson’s data strategy and leading its implementation from an operational and cultural perspective. She will oversee the Data...
MD Anderson to pay tribute to legendary Emil J Freireich, M.D., in virtual celebration on Sept. 23
The University of Texas MD Anderson Cancer Center will celebrate the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual...
Long-term benefit of SABR for operable early-stage NSCLC shown in new study
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was...
Omer Sultan joins MD Anderson as new Chief Financial Officer
The University of Texas MD Anderson Cancer Center today named Omer Sultan senior vice president and chief financial officer (CFO). With his...
MD Anderson again ranks No. 1 in cancer by U.S. News & World Report
The University of Texas MD Anderson Cancer Center again has been named No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual...
Targeted therapy pralsetinib safely and effectively treats lung and thyroid cancers with RET alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers,...
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for...
MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients...
MD Anderson celebrates World Cancer Day and the global initiative to end cancer
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Day, Feb. 4, to honor the international effort to eliminate...